Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

UBS
Johnson and Johnson
Mallinckrodt
Teva
Harvard Business School
McKesson
Colorcon
Novartis
QuintilesIMS
Queensland Health

Generated: January 18, 2018

DrugPatentWatch Database Preview

ZANTAC 300 Drug Profile

« Back to Dashboard

Which patents cover Zantac 300, and what generic alternatives are available?

Zantac 300 is a drug marketed by Glaxosmithkline and Glaxo Grp Ltd and is included in two NDAs.

The generic ingredient in ZANTAC 300 is ranitidine hydrochloride. There are forty-three drug master file entries for this compound. One hundred and forty-one suppliers are listed for this compound. Additional details are available on the ranitidine hydrochloride profile page.

US Patents and Regulatory Information for ZANTAC 300

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline ZANTAC 300 ranitidine hydrochloride CAPSULE;ORAL 020095-002 Mar 8, 1994 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Glaxo Grp Ltd ZANTAC 300 ranitidine hydrochloride TABLET;ORAL 018703-002 Dec 9, 1985 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for ZANTAC 300

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxo Grp Ltd ZANTAC 300 ranitidine hydrochloride TABLET;ORAL 018703-002 Dec 9, 1985 ➤ Subscribe ➤ Subscribe
Glaxosmithkline ZANTAC 300 ranitidine hydrochloride CAPSULE;ORAL 020095-002 Mar 8, 1994 ➤ Subscribe ➤ Subscribe
Glaxosmithkline ZANTAC 300 ranitidine hydrochloride CAPSULE;ORAL 020095-002 Mar 8, 1994 ➤ Subscribe ➤ Subscribe
Glaxo Grp Ltd ZANTAC 300 ranitidine hydrochloride TABLET;ORAL 018703-002 Dec 9, 1985 ➤ Subscribe ➤ Subscribe
Glaxo Grp Ltd ZANTAC 300 ranitidine hydrochloride TABLET;ORAL 018703-002 Dec 9, 1985 ➤ Subscribe ➤ Subscribe
Glaxosmithkline ZANTAC 300 ranitidine hydrochloride CAPSULE;ORAL 020095-002 Mar 8, 1994 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
US Department of Justice
Dow
Cerilliant
AstraZeneca
Covington
Mallinckrodt
Chubb
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot